Arcturus Therapeutics Holdings (ARCT) Panoramica del titolo
Arcturus Therapeutics Holdings Inc. è un'azienda produttrice di farmaci a base di RNA messaggero e si concentra sullo sviluppo di farmaci per malattie rare del fegato e dell'apparato respiratorio. Maggiori dettagli
| Punteggio fiocco di neve | |
|---|---|
| Valutazione | 2/6 |
| Crescita futura | 2/6 |
| Prestazioni passate | 0/6 |
| Salute finanziaria | 6/6 |
| Dividendi | 0/6 |
ARCT Community Fair Values
Create NarrativeSee what 46 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
LO
Lou_Basenese
Community ContributorUS$7.6FV • 75.1% sottovalutato sconto intrinseco
5022.2%Revenue growth p.a.
3.7k
22
2
54
Concorrenti di Arcturus Therapeutics Holdings Inc.
Storia dei prezzi e prestazioni
| Prezzi storici delle azioni | |
|---|---|
| Prezzo attuale dell'azione | US$8.62 |
| Massimo di 52 settimane | US$24.17 |
| Minimo di 52 settimane | US$5.85 |
| Beta | 2.44 |
| Variazione di 1 mese | 11.66% |
| Variazione a 3 mesi | 15.39% |
| Variazione di 1 anno | -31.04% |
| Variazione a 3 anni | -67.57% |
| Variazione a 5 anni | -71.41% |
| Variazione dall'IPO | -13.89% |
Notizie e aggiornamenti recenti
ARCT: Future Execution Risks Will Drive Sensitivity To Pipeline Milestones
Analysts have modestly adjusted the average price target on Arcturus Therapeutics Holdings, reflecting updated assumptions around program execution, mixed Q4 commentary, and the removal of certain COVID-related profit share contributions, while still citing ongoing interest in cystic fibrosis and ornithine transcarbamylase deficiency programs. Analyst Commentary Recent Street research on Arcturus Therapeutics Holdings reflects a mix of cautious and constructive views, with several firms recalibrating their models after the latest Q4 update.ARCT: Fair Value View Balances Execution Concerns With Pipeline Progress
Analysts have raised the fair value estimate for Arcturus Therapeutics Holdings to $8.00 from $7.00, based on updated models that incorporate more conservative revenue expectations, higher projected profit margins and recent Street research that reduces longer term targets while still highlighting clinical progress in key programs. Analyst Commentary Recent Street research around Arcturus Therapeutics shows a mix of cautious and constructive views, with several firms revising their models after the latest quarterly update and pipeline commentary.
ARCT: CF And OTCD mRNA Pipeline Progress Will Drive Future Upside
Analysts have reset their models on Arcturus Therapeutics Holdings, cutting the implied fair value estimate from about $72 to about $55 as they factor in more conservative profit margins, a slightly higher discount rate, removal of COVID-related upside, and a sharper focus on the cystic fibrosis and ornithine transcarbamylase deficiency pipelines. Analyst Commentary Recent Street research on Arcturus Therapeutics Holdings shows a wide range of fair value views, but several bullish analysts continue to see upside potential even after cutting price targets and removing COVID-related assumptions from their models.ARCT: Elevated Future P/E Assumptions Will Pressure Execution Risk Outlook
Analysts have raised their price target on Arcturus Therapeutics Holdings to $7.00, reflecting updated assumptions around discount rates, revenue growth, margins and future P/E, supported by a recent bullish initiation from Roth Capital and similar research commentary from other firms. Analyst Commentary While some research has turned more constructive, you are also seeing a thread of caution in recent commentary on Arcturus Therapeutics Holdings.Recent updates
ARCT: Future Execution Risks Will Drive Sensitivity To Pipeline Milestones
Analysts have modestly adjusted the average price target on Arcturus Therapeutics Holdings, reflecting updated assumptions around program execution, mixed Q4 commentary, and the removal of certain COVID-related profit share contributions, while still citing ongoing interest in cystic fibrosis and ornithine transcarbamylase deficiency programs. Analyst Commentary Recent Street research on Arcturus Therapeutics Holdings reflects a mix of cautious and constructive views, with several firms recalibrating their models after the latest Q4 update.ARCT: Fair Value View Balances Execution Concerns With Pipeline Progress
Analysts have raised the fair value estimate for Arcturus Therapeutics Holdings to $8.00 from $7.00, based on updated models that incorporate more conservative revenue expectations, higher projected profit margins and recent Street research that reduces longer term targets while still highlighting clinical progress in key programs. Analyst Commentary Recent Street research around Arcturus Therapeutics shows a mix of cautious and constructive views, with several firms revising their models after the latest quarterly update and pipeline commentary.ARCT: CF And OTCD mRNA Pipeline Progress Will Drive Future Upside
Analysts have reset their models on Arcturus Therapeutics Holdings, cutting the implied fair value estimate from about $72 to about $55 as they factor in more conservative profit margins, a slightly higher discount rate, removal of COVID-related upside, and a sharper focus on the cystic fibrosis and ornithine transcarbamylase deficiency pipelines. Analyst Commentary Recent Street research on Arcturus Therapeutics Holdings shows a wide range of fair value views, but several bullish analysts continue to see upside potential even after cutting price targets and removing COVID-related assumptions from their models.ARCT: Elevated Future P/E Assumptions Will Pressure Execution Risk Outlook
Analysts have raised their price target on Arcturus Therapeutics Holdings to $7.00, reflecting updated assumptions around discount rates, revenue growth, margins and future P/E, supported by a recent bullish initiation from Roth Capital and similar research commentary from other firms. Analyst Commentary While some research has turned more constructive, you are also seeing a thread of caution in recent commentary on Arcturus Therapeutics Holdings.ARCT: Bullish Coverage And Execution Risks Will Shape Fairly Valued Outlook
Analysts have raised their price target on Arcturus Therapeutics Holdings to $7.00, up from $7, citing a new bullish initiation that highlights the company’s fair value, long term revenue and margin assumptions, and expected future P/E as key supports for the revised view. Analyst Commentary While the new initiation frames US$7.00 as a reasonable reference point, bearish analysts continue to flag risks that could pressure the stock if execution does not line up with the assumptions behind that fair value, especially around long term revenue, margins, and the P/E that is being used in models.Arcturus Therapeutics: Two Catalysts, One Runway, And A Stock Priced For Failure
Feb 12ARCT: Bullish Coverage And Higher Future P/E Will Frame Execution Risks
Analysts have lifted their price target on Arcturus Therapeutics Holdings, pointing to a fair value view of US$7.00 per share. This is supported by a slightly lower discount rate, a more conservative revenue growth outlook and a higher assumed future P/E multiple, with recent bullish Street research helping to justify the updated stance.ARCT: Neutral Downgrade And Fair Value View Will Frame Execution Risks
Analysts reduced their fair value estimate for Arcturus Therapeutics Holdings from US$9.00 to US$7.00, citing updated assumptions for discount rate, revenue growth, profit margin and future P/E following the recent downgrade to Neutral by Street research. Analyst Commentary Bearish analysts are signaling a more cautious stance on Arcturus Therapeutics Holdings, with the recent downgrade to Neutral framing the stock as more of a wait and see situation rather than a clear opportunity at current levels.ARCT: Neutral Downgrade Will Set Up Potential Upside Repricing
Analysts have reduced their price target for Arcturus Therapeutics Holdings from US$42 to US$9, citing updated assumptions for the discount rate, revenue trends, and a lower forward P/E multiple, along with recent rating changes such as the downgrade to Neutral. Analyst Commentary Bearish analysts are signaling a more cautious stance on Arcturus Therapeutics Holdings, with the move to a Neutral rating reinforcing the cut in the price target from US$42 to US$9.ARCT: Orphan mRNA Cystic Fibrosis Program Will Drive Future Upside
Analysts lowered their price target on Arcturus Therapeutics Holdings to 72 dollars from 128.81 dollars, reflecting a more cautious stance despite higher projected revenue growth and profit margins. They are reassessing valuation multiples and risk following recent rating actions.The Market Doesn't Like What It Sees From Arcturus Therapeutics Holdings Inc.'s (NASDAQ:ARCT) Revenues Yet As Shares Tumble 52%
Oct 28
Improved Revenues Required Before Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) Stock's 32% Jump Looks Justified
Aug 29
Late-Stage Trials And Vaccine Partnerships Will Strengthen Market Potential
Analysts maintained an Overweight rating and reiterated a $47 price target for Arcturus Therapeutics Holdings, citing anticipated positive catalysts from the upcoming Phase 2 Cystic Fibrosis program readout in early Q3, while the consensus analyst price target remained unchanged at $70.89. Analyst Commentary Addition of an "upside 90-day catalyst watch" due to the upcoming Cystic Fibrosis program catalyst expected in early Q3.Is Arcturus Therapeutics Holdings (NASDAQ:ARCT) Weighed On By Its Debt Load?
Jul 31Arcturus Therapeutics Holdings Inc.'s (NASDAQ:ARCT) Price Is Right But Growth Is Lacking After Shares Rocket 41%
May 04
KOSTAIVE Approval And Upcoming Vaccine Trials Will Open New Markets
European approval of the mRNA COVID-19 vaccine could significantly boost sales through broader market access in 31 countries.Benign Growth For Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) Underpins Stock's 26% Plummet
Mar 20Analysts Have Lowered Expectations For Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) After Its Latest Results
Mar 09Arcturus: Downgrading As mRNA Promise Meets Market Reality
Jan 28Arcturus: LUNAR-CF For CF Presses On With 1st Half Of 2025 Interim Data
Nov 14Improved Revenues Required Before Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) Stock's 28% Jump Looks Justified
Oct 04Here's Why We're Not Too Worried About Arcturus Therapeutics Holdings' (NASDAQ:ARCT) Cash Burn Situation
Sep 06High-Risk, High-Reward: Arcturus Nears Commercialization Of Kostaive Vaccine
Aug 09Arcturus: A Hidden Gem In The Biotech Sector
Jun 08Arcturus Therapeutics Holdings Inc.'s (NASDAQ:ARCT) Share Price Boosted 45% But Its Business Prospects Need A Lift Too
May 29Arcturus Therapeutics' ARCT-032: Might Be The Next Breakthrough In Cystic Fibrosis
Apr 23Arcturus Therapeutics Holdings (NASDAQ:ARCT) Is In A Strong Position To Grow Its Business
Apr 09Arcturus Therapeutics Holdings Inc.'s (NASDAQ:ARCT) Price Is Right But Growth Is Lacking
Feb 06Arcturus: H1 2024 Rare Disease Drug Data On Deck
Jan 31Does Arcturus Therapeutics Holdings (NASDAQ:ARCT) Have A Healthy Balance Sheet?
Jan 11Are Investors Undervaluing Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) By 46%?
Dec 14Arcturus Therapeutics Holdings Inc.'s (NASDAQ:ARCT) Shares Lagging The Industry But So Is The Business
Sep 14Some Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) Analysts Just Made A Major Cut To Next Year's Estimates
Aug 08Calculating The Fair Value Of Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT)
Jul 19Broker Revenue Forecasts For Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) Are Surging Higher
May 18Rendimenti per gli azionisti
| ARCT | US Biotechs | US Mercato | |
|---|---|---|---|
| 7D | 1.8% | -2.2% | 0.6% |
| 1Y | -31.0% | 30.4% | 28.7% |
Ritorno vs Industria: ARCT ha avuto una performance inferiore rispetto al US Biotechs che ha registrato un rendimento 30.4 % nell'ultimo anno.
Rendimento vs Mercato: ARCT ha avuto una performance inferiore al mercato US che ha registrato un rendimento 28.7 % nell'ultimo anno.
Volatilità dei prezzi
| ARCT volatility | |
|---|---|
| ARCT Average Weekly Movement | 8.0% |
| Biotechs Industry Average Movement | 10.8% |
| Market Average Movement | 7.2% |
| 10% most volatile stocks in US Market | 16.2% |
| 10% least volatile stocks in US Market | 3.3% |
Prezzo delle azioni stabile: ARCT non ha avuto una volatilità dei prezzi significativa negli ultimi 3 mesi rispetto al mercato US.
Volatilità nel tempo: La volatilità settimanale di ARCT è diminuita da 13% a 8% nell'ultimo anno.
Informazioni sull'azienda
| Fondato | I dipendenti | AMMINISTRATORE DELEGATO | Sito web |
|---|---|---|---|
| 2013 | 109 | Joe Payne | arcturusrx.com |
Arcturus Therapeutics Holdings Inc. è un'azienda produttrice di farmaci a base di RNA messaggero e si concentra sullo sviluppo di terapie per malattie rare del fegato e dell'apparato respiratorio. Le sue piattaforme tecnologiche comprendono STARR, una piattaforma tecnologica di mRNA autoamplificante, e LUNAR, un sistema di rilascio mediato da lipidi. L'azienda sviluppa anche ARCT-032 (LUNAR-CF), un candidato terapeutico a base di mRNA per la fibrosi cistica, in fase di sviluppo clinico di Fase 2, e ARCT-810 (LUNAR-OTC), in fase di sviluppo clinico di Fase 2 per risolvere il deficit di ornitina transcarbamilasi (OTC).
Arcturus Therapeutics Holdings Inc. Riepilogo dei fondamenti
| ARCT statistiche fondamentali | |
|---|---|
| Capitalizzazione di mercato | US$238.75m |
| Utili (TTM) | -US$65.78m |
| Ricavi(TTM) | US$82.03m |
3.0x
Rapporto P/S-3.7x
Rapporto P/EARCT è sopravvalutato?
Vedi Fair Value e analisi di valutazioneUtili e ricavi
| ARCT Conto economico (TTM) | |
|---|---|
| Ricavi | US$82.03m |
| Costo del fatturato | US$112.21m |
| Profitto lordo | -US$30.18m |
| Altre spese | US$35.60m |
| Utili | -US$65.78m |
Ultimi utili riportati
Dec 31, 2025
Prossima data di guadagno
May 07, 2026
| Utile per azione (EPS) | -2.31 |
| Margine lordo | -36.79% |
| Margine di profitto netto | -80.19% |
| Rapporto debito/patrimonio netto | 0% |
Come si è comportato ARCT nel lungo periodo?
Vedi performance storica e confrontoAnalisi aziendale e situazione dei dati finanziari
| Dati | Ultimo aggiornamento (ora UTC) |
|---|---|
| Analisi dell'azienda | 2026/04/30 11:50 |
| Prezzo dell'azione a fine giornata | 2026/04/30 00:00 |
| Utili | 2025/12/31 |
| Utili annuali | 2025/12/31 |
Fonti dei dati
I dati utilizzati nella nostra analisi aziendale provengono da S&P Global Market Intelligence LLC. I seguenti dati sono utilizzati nel nostro modello di analisi per generare questo report. I dati sono normalizzati, il che può comportare un ritardo nella disponibilità della fonte.
| Pacchetto | Dati | Tempistica | Esempio Fonte USA * |
|---|---|---|---|
| Dati finanziari della società | 10 anni |
| |
| Stime di consenso degli analisti | +3 anni |
|
|
| Prezzi di mercato | 30 anni |
| |
| Proprietà | 10 anni |
| |
| Gestione | 10 anni |
| |
| Sviluppi principali | 10 anni |
|
* Esempio per i titoli statunitensi, per i titoli non statunitensi si utilizzano forme e fonti normative equivalenti.
Se non specificato, tutti i dati finanziari si basano su un periodo annuale ma vengono aggiornati trimestralmente. Si tratta dei cosiddetti dati TTM (Trailing Twelve Month) o LTM (Last Twelve Month). Per saperne di più.
Modello di analisi e Snowflake
I dettagli del modello di analisi utilizzato per generare questo report sono disponibili sulla nostra pagina Github; abbiamo anche guide su come utilizzare i nostri report e tutorial su Youtube.
Scoprite il team di livello mondiale che ha progettato e realizzato il modello di analisi Simply Wall St.
Metriche di settore e industriali
Le nostre metriche di settore e di sezione sono calcolate ogni 6 ore da Simply Wall St; i dettagli del nostro processo sono disponibili su Github.
Fonti analitiche
Arcturus Therapeutics Holdings Inc. è coperta da 23 analisti. 12 di questi analisti ha fornito le stime di fatturato o di utile utilizzate come input per il nostro report. Le stime degli analisti vengono aggiornate nel corso della giornata.
| Analista | Istituzione |
|---|---|
| Huidong Wang | Barclays |
| Mayank Mamtani | B. Riley Securities, Inc. |
| Thomas Shrader | BTIG |